MA33298B1 - Formulations liquides de sels de 1-[2-(2,4-diméthylphénylsulfanyl)-phényl]pipérazine - Google Patents
Formulations liquides de sels de 1-[2-(2,4-diméthylphénylsulfanyl)-phényl]pipérazineInfo
- Publication number
- MA33298B1 MA33298B1 MA34385A MA34385A MA33298B1 MA 33298 B1 MA33298 B1 MA 33298B1 MA 34385 A MA34385 A MA 34385A MA 34385 A MA34385 A MA 34385A MA 33298 B1 MA33298 B1 MA 33298B1
- Authority
- MA
- Morocco
- Prior art keywords
- formulations
- dimethylphenylsulfanil
- phenylpiperazine
- salt liquids
- liquids
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title 1
- 239000007788 liquid Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- YZTJYBJCZXZGCT-UHFFFAOYSA-N phenylpiperazine Chemical compound C1CNCCN1C1=CC=CC=C1 YZTJYBJCZXZGCT-UHFFFAOYSA-N 0.000 title 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 abstract 2
- 235000014655 lactic acid Nutrition 0.000 abstract 1
- 239000004310 lactic acid Substances 0.000 abstract 1
- 239000012669 liquid formulation Substances 0.000 abstract 1
- YQNWZWMKLDQSAC-UHFFFAOYSA-N vortioxetine Chemical class CC1=CC(C)=CC=C1SC1=CC=CC=C1N1CCNCC1 YQNWZWMKLDQSAC-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
- C07C59/08—Lactic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Lubricants (AREA)
Abstract
Des formulations liquides de sels d'addition d'acide lactique de 1-[2-(2,4-diméthylphénylsulfanyl)phényl]pipérazine sont décrites.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21454009P | 2009-04-24 | 2009-04-24 | |
| DKPA200900531 | 2009-04-24 | ||
| PCT/DK2010/050084 WO2010121621A1 (fr) | 2009-04-24 | 2010-04-16 | Formulations liquides de sels de 1-[2-(2,4-diméthylphénylsulfanyl)- phényl]pipérazine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA33298B1 true MA33298B1 (fr) | 2012-05-02 |
Family
ID=42669509
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA34385A MA33298B1 (fr) | 2009-04-24 | 2010-04-16 | Formulations liquides de sels de 1-[2-(2,4-diméthylphénylsulfanyl)-phényl]pipérazine |
Country Status (35)
| Country | Link |
|---|---|
| US (4) | US8940746B2 (fr) |
| EP (1) | EP2421534B1 (fr) |
| JP (1) | JP5722879B2 (fr) |
| KR (1) | KR101779214B1 (fr) |
| CN (2) | CN104693145A (fr) |
| AR (2) | AR076400A1 (fr) |
| AU (1) | AU2010238946B2 (fr) |
| BR (1) | BRPI1015338C1 (fr) |
| CA (1) | CA2759456C (fr) |
| CL (1) | CL2011002631A1 (fr) |
| CO (1) | CO6450649A2 (fr) |
| CR (1) | CR20110554A (fr) |
| DK (1) | DK2421534T3 (fr) |
| DO (2) | DOP2011000319A (fr) |
| EA (1) | EA021122B1 (fr) |
| ES (1) | ES2512719T3 (fr) |
| GE (1) | GEP20135938B (fr) |
| HK (1) | HK1206732A1 (fr) |
| HR (1) | HRP20140880T1 (fr) |
| IL (1) | IL215362A0 (fr) |
| MA (1) | MA33298B1 (fr) |
| MX (1) | MX2011011119A (fr) |
| MY (1) | MY155288A (fr) |
| NZ (1) | NZ596431A (fr) |
| PL (1) | PL2421534T3 (fr) |
| PT (1) | PT2421534E (fr) |
| RS (1) | RS53539B1 (fr) |
| SG (1) | SG175124A1 (fr) |
| SI (1) | SI2421534T1 (fr) |
| SM (1) | SMT201400159B (fr) |
| TN (1) | TN2011000504A1 (fr) |
| TW (1) | TWI461224B (fr) |
| UA (1) | UA106985C2 (fr) |
| WO (1) | WO2010121621A1 (fr) |
| ZA (1) | ZA201107731B (fr) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5722879B2 (ja) | 2009-04-24 | 2015-05-27 | ハー・ルンドベック・アクチエゼルスカベット | １−［２−（２，４−ジメチルフェニルスルファニル）フェニル］ピペラジンの塩の液体製剤 |
| US9499504B2 (en) | 2012-09-19 | 2016-11-22 | Sandoz Ag | Crystalline form of vortioxetine hydrobromide |
| AU2014286308B2 (en) * | 2013-07-01 | 2018-05-10 | Lek Pharmaceuticals D.D. | 1-[2-(2,4-dimethylphenylsulfanyl) phenyl]piperazine acetate in crystalline form |
| US9822086B2 (en) | 2014-01-31 | 2017-11-21 | Egis Gyogyszergyar Zrt. | Process for the preparation of vortioxetine salts |
| CN104146953A (zh) * | 2014-07-24 | 2014-11-19 | 李雪梅 | 一种氢溴酸沃替西汀注射液 |
| CN104119299B (zh) * | 2014-08-13 | 2016-08-17 | 北京蓝贝望生物医药科技股份有限公司 | 沃赛汀或沃替西汀的氢溴酸盐 |
| CN104119298B (zh) * | 2014-08-13 | 2016-08-24 | 北京蓝贝望生物医药科技股份有限公司 | 氢溴酸沃赛汀或氢溴酸沃替西汀 |
| GB201419261D0 (en) * | 2014-10-29 | 2014-12-10 | Therakind Ltd | Formulations |
| WO2016125190A2 (fr) | 2015-02-04 | 2016-08-11 | Mylan Laboratories Limited | Nouvelles formes cristallines de vortioxétine, prémélanges, et procédés pour la préparation de ceux-ci |
| JO3456B1 (ar) * | 2015-05-13 | 2020-07-05 | H Lundbeck As | فيروتيوكسيتين بيروجلوتامات |
| US20190040028A1 (en) | 2016-02-08 | 2019-02-07 | Aaa Chemistry Aps | Arylation of aliphatic amines |
| AU2017288456A1 (en) | 2016-07-01 | 2018-12-13 | H. Lundbeck A/S | Vortioxetine dosing regimes for fast onset of antidepressant effect |
| CN106518807A (zh) * | 2016-09-17 | 2017-03-22 | 北京万全德众医药生物技术有限公司 | 乳酸沃替西汀晶型的制备方法 |
| US10519121B2 (en) | 2016-12-30 | 2019-12-31 | Apicore Us Llc | Process and novel polymorphic form of vortioxetine and its pharmaceutically acceptable salts |
| CN107011289A (zh) * | 2017-03-10 | 2017-08-04 | 万全万特制药（厦门）有限公司 | 沃替西汀β晶型的制备方法 |
| GB2564887A (en) * | 2017-07-26 | 2019-01-30 | Azad Pharmaceutical Ingredients Ag | New route of synthesis to vortioxetine salts |
| WO2020087031A1 (fr) | 2018-10-26 | 2020-04-30 | The Research Foundation For The State University Of New York | Combinaison d'un inhibiteur de réabsorption spécifique de la sérotonine et d'un agoniste partiel du récepteur de la sérotonine 1a pour réduire la dyskinésie induite par l-dopa |
| JP2023520016A (ja) | 2020-04-03 | 2023-05-15 | ハー・ルンドベック・アクチエゼルスカベット | 感情鈍麻の予防又は処置のための１－［２－（２，４－ジメチルフェニルスルファニル）－フェニル］ピペラジン |
| EP4681702A1 (fr) * | 2024-07-16 | 2026-01-21 | PharmaPath S.A. | Solution orale comprenant hydrobromure de vortioxétine |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA81749C2 (uk) * | 2001-10-04 | 2008-02-11 | Х. Луннбек А/С | Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну |
| EP1626720B1 (fr) | 2003-04-04 | 2008-09-03 | H. Lundbeck A/S | Derives de 4-(2-phenylsulfanyl-phenyl)-piperidines en tant qu'inhibiteurs de reabsorption de la serotonine |
| CA2656057C (fr) * | 2006-06-16 | 2012-10-02 | H. Lundbeck A/S | Formes cristallines de la 4-[2-(4-methylphenylsulfanyl)-phenyl] piperidine avec inhibition de la reabsorption de la serotonine et de la norepinephrine en combinaison pour le traitement de la douleur neuropathique |
| ZA200810017B (en) * | 2006-06-16 | 2010-04-28 | Lundbeck & Co As H | 1- [2- (2, 4-Dimethylphenylsulfanyl) -phenyl] piperazine as a compound with combined serotonin Reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
| TWI405588B (zh) * | 2007-03-20 | 2013-08-21 | Lundbeck & Co As H | ４-〔２-（４-甲苯基硫基）-苯基〕哌啶之鹽類的液體調配物 |
| TW200848411A (en) * | 2007-03-20 | 2008-12-16 | Lundbeck & Co As H | Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine |
| JP5722879B2 (ja) | 2009-04-24 | 2015-05-27 | ハー・ルンドベック・アクチエゼルスカベット | １−［２−（２，４−ジメチルフェニルスルファニル）フェニル］ピペラジンの塩の液体製剤 |
-
2010
- 2010-04-16 JP JP2012506342A patent/JP5722879B2/ja active Active
- 2010-04-16 PT PT107141640T patent/PT2421534E/pt unknown
- 2010-04-16 SI SI201030759T patent/SI2421534T1/sl unknown
- 2010-04-16 SG SG2011073384A patent/SG175124A1/en unknown
- 2010-04-16 EA EA201171287A patent/EA021122B1/ru not_active IP Right Cessation
- 2010-04-16 ES ES10714164.0T patent/ES2512719T3/es active Active
- 2010-04-16 BR BRPI1015338A patent/BRPI1015338C1/pt active IP Right Grant
- 2010-04-16 US US13/265,564 patent/US8940746B2/en active Active
- 2010-04-16 CA CA2759456A patent/CA2759456C/fr active Active
- 2010-04-16 NZ NZ596431A patent/NZ596431A/xx unknown
- 2010-04-16 CN CN201510093852.4A patent/CN104693145A/zh active Pending
- 2010-04-16 GE GEAP201012423A patent/GEP20135938B/en unknown
- 2010-04-16 KR KR1020117025009A patent/KR101779214B1/ko active Active
- 2010-04-16 AU AU2010238946A patent/AU2010238946B2/en active Active
- 2010-04-16 EP EP10714164.0A patent/EP2421534B1/fr active Active
- 2010-04-16 TW TW099111946A patent/TWI461224B/zh active
- 2010-04-16 HR HRP20140880AT patent/HRP20140880T1/hr unknown
- 2010-04-16 CN CN2010800171058A patent/CN102405048A/zh active Pending
- 2010-04-16 MA MA34385A patent/MA33298B1/fr unknown
- 2010-04-16 PL PL10714164T patent/PL2421534T3/pl unknown
- 2010-04-16 DK DK10714164.0T patent/DK2421534T3/da active
- 2010-04-16 RS RSP20140505 patent/RS53539B1/sr unknown
- 2010-04-16 MX MX2011011119A patent/MX2011011119A/es active IP Right Grant
- 2010-04-16 WO PCT/DK2010/050084 patent/WO2010121621A1/fr not_active Ceased
- 2010-04-16 UA UAA201113335A patent/UA106985C2/uk unknown
- 2010-04-16 MY MYPI2011004813A patent/MY155288A/en unknown
- 2010-04-23 AR ARP100101364A patent/AR076400A1/es not_active Application Discontinuation
-
2011
- 2011-09-25 IL IL215362A patent/IL215362A0/en active IP Right Grant
- 2011-10-07 TN TNP2011000504A patent/TN2011000504A1/en unknown
- 2011-10-19 CR CR20110554A patent/CR20110554A/es unknown
- 2011-10-20 DO DO2011000319A patent/DOP2011000319A/es unknown
- 2011-10-21 CL CL2011002631A patent/CL2011002631A1/es unknown
- 2011-10-21 ZA ZA2011/07731A patent/ZA201107731B/en unknown
- 2011-10-24 CO CO11143307A patent/CO6450649A2/es active IP Right Grant
-
2012
- 2012-07-27 DO DO2012000211A patent/DOP2012000211A/es unknown
-
2014
- 2014-10-29 SM SM201400159T patent/SMT201400159B/xx unknown
- 2014-12-11 US US14/567,003 patent/US9475748B2/en active Active
-
2015
- 2015-07-29 HK HK15107256.7A patent/HK1206732A1/xx unknown
-
2016
- 2016-09-21 US US15/271,543 patent/US10034876B2/en active Active
-
2018
- 2018-06-27 US US16/020,799 patent/US10857149B2/en active Active
-
2021
- 2021-05-10 AR ARP210101276A patent/AR122051A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA33298B1 (fr) | Formulations liquides de sels de 1-[2-(2,4-diméthylphénylsulfanyl)-phényl]pipérazine | |
| UA102336C2 (uk) | N1-ПІРАЗОЛСПІРОКЕТОНИ ЯК ІНГІБІТОРИ АЦЕТИЛ-СоА-КАРБОКСИЛАЗ | |
| EA200901609A1 (ru) | Амиды пиразолкарбоновой кислоты, применимые в качестве микробиоцидов | |
| MX2011012344A (es) | Sales de disacarina, acido difumarico, acido di-1-hidroxi-2-naftoi co y acido monobenzoico del 2-(4-((2-amino-4-metil-6-(pentilamino) pirimidin-5-il)metil)fenil)acetato de 4-(dimetilamino) butilo. | |
| EA201100875A1 (ru) | Новые пиразол-4-n-алкоксикарбоксамиды в качестве микробиоцидов | |
| EA201001313A1 (ru) | Гирбицидный состав | |
| PH12013500247A1 (en) | Heterocyclic compound and use thereof | |
| MX2009008700A (es) | Diaminopirimidinas como fungicidas. | |
| EA200870217A1 (ru) | 4-арил-2-аминопиримидины или 4-арил-2-аминоалкилпиримидины в качестве модуляторов jak-2 и содержащие их фармацевтические композиции | |
| SG178952A1 (en) | Chemical compounds | |
| UA108219C2 (uk) | Протипаразитарні дигідроазолові сполуки та композиція, яка їх містить (варіанти) | |
| EA201391288A1 (ru) | Производные пиразолоспирокетонов для применения в качестве ингибиторов ацетил-коа-карбоксилаз | |
| GEP20125712B (en) | Method for preparation of piperazine compounds and hydrochloride salts thereof | |
| EA201300423A1 (ru) | Кристаллический конъюгат налоксол-peg | |
| EA201101097A1 (ru) | Новые микробиоциды | |
| EA201691538A1 (ru) | Способ получения солей вортиоксетина | |
| EA201101301A1 (ru) | Натриевая соль 5-циклопропил-2-{[2-(2,6-дифторфенил)пиримидин-5-ил]амино}бензойной кислоты в качестве ингибиторов dhodh | |
| MX2009007265A (es) | Sales, composiciones liquidas acuosas que cotienen sales de acido s-(+)-abscisico y metodos para su preparacion. | |
| EA201100594A1 (ru) | Триазольные и имидазольные соединения, их применение, а также содержащие их средства | |
| EP2582240A4 (fr) | Composition herbicide à base de sel d'acide picolinique | |
| EA201100754A1 (ru) | [4-(1-аминоэтил)циклогексил]метиламины в качестве антибактериальных средств | |
| SI2608789T1 (sl) | Terapevtske uporabe 1-(2-(2,4-dimetil-fenilsulfanil) fenil) piperazina | |
| IN2012DN01223A (fr) | ||
| IN2012DN02698A (fr) | ||
| CY1115793T1 (el) | Υγρα σκευασματα αλατων 1-[2-(2,4-διμεθυλοφαινυλοσουλφανυλο)φαινυλο]πιπεραζινης |